The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA
Open accessAbstract
The results of administering escalating, i.v. doses of targeted nanoparticles containing a siRNA targeting the M2 subunit of ribonucleotide reductase to non-human primates are reported. The nanoparticles consist of a synthetic delivery system that uses a linear, cyclodextrin-containing polycation, transferrin (Tf) protein targeting ligand, and siRNA. When administered to cynomolgus monkeys at doses of 3 and 9 mg siRNA/kg, the nanoparticles are well tolerated. At 27 mg siRNA/kg, elevated levels of blood urea nitrogen and creatinine are observed that are indicative of kidney toxicity. Mild elevations in alanine amino transferase and aspartate transaminase at this dose level indicate that the liver is also affected to some extent. Analysis of complement factors does not reveal any changes that are clearly attributable to dosing with the nanoparticle formulation. Detection of increased IL-6 levels in all animals at 27 mg siRNA/kg and increased IFN-γ in one animal indicate that this high dose level produces a mild immune response. Overall, no clinical signs of toxicity clearly attributable to treatment are observed. The multiple administrations spanning a period of 17–18 days enable assessment of antibody formation against the human Tf component of the formulation. Low titers of anti-Tf antibodies are detected, but this response is not associated with any manifestations of a hypersensitivity reaction upon readministration of the targeted nanoparticle. Taken together, the data presented show that multiple, systemic doses of targeted nanoparticles containing nonchemically modified siRNA can safely be administered to non-human primates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Bartlett, D. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj439 · Cited by 592
Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Self-citationIshida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.005 · Cited by 557
Transferrin receptors in human tissues: their distribution and possible clinical relevance.
Gatter, K. C., Brown, G., Trowbridge, I. S., Woolston, R. E., & Mason, D. Y. (1983) · Journal of Clinical Pathology · doi:10.1136/jcp.36.5.539 · Cited by 531
Aptamer mediated siRNA delivery
Chu, T. C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl388 · Cited by 446
Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
Li, B.-J., Tang, Q., Cheng, D., Qin, C., Xie, F. Y., Wei, Q., Xu, J., Liu, Y., Zheng, B.-J., Woodle, M. C., et al. (2005) · Nature Medicine · doi:10.1038/nm1280 · Cited by 433
Sioud, M. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.03.013 · Cited by 418
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†
Morrissey, D. V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J. A., Dickinson, B., McSwiggen, J. A., Vargeese, C., Bowman, K., Shaffer, C. S., et al. (2005) · Hepatology · doi:10.1002/hep.20702 · Cited by 290
Cationic liposome-mediated delivery of siRNAs in adult mice
Sioud, M., & Sørensen, D. R. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.057 · Cited by 286
Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles
Bartlett, D. W., & Davis, M. E. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0603539 · Cited by 283
Self-citationJudge, A., McClintock, K., Phelps, J. R., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.014 · Cited by 280
Drug-Induced Phospholipidosis: Are There Functional Consequences?
Reasor, M. J., & Kacew, S. (2001) · Experimental Biology and Medicine · doi:10.1177/153537020122600903 · Cited by 265
Szebeni, J., Baranyi, L., Savay, S., Milosevits, J., Bunger, R., Laverman, P., Metselaar, J. M., Storm, G., Chanan-Khan, A., Liebes, L., et al. (2002) · Journal of Liposome Research · doi:10.1081/lpr-120004790 · Cited by 212
Semple, S. C., Harasym, T. O., Clow, K. A., Ansell, S. M., Klimuk, S. K., & Hope, M. J. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078113 · Cited by 211
Henry, S. P., Giclas, P. C., Leeds, J., Pangburn, M., Auletta, C., Levin, A. A., & Kornbrust, D. J. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36667-4 · Cited by 204
Self-citationPun, S. H., Tack, F., Bellocq, N. C., Cheng, J., Grubbs, B. H., Jensen, G. S., Davis, M. E., Brewster, M., Janicot, M., Janssens, B., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.7.918 · Cited by 201
Self-citationLack of interferon response in animals to naked siRNAs
Heidel, J. D., Hu, S., Liu, X. F., Triche, T. J., & Davis, M. E. (2004) · Nature Biotechnology · doi:10.1038/nbt1038 · Cited by 183
Self-citationSzebeni, J., Baranyi, L., Savay, S., Bodo, M., Morse, D. S., Basta, M., Stahl, G. L., Bünger, R., & Alving, C. R. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.3.h1319 · Cited by 171
Heidel, J. D., Liu, J. Y.-C., Yen, Y., Zhou, B., Heale, B. S. E., Rossi, J. J., Bartlett, D. W., & Davis, M. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2218 · Cited by 160
Self-citationYu, R. Z., Baker, B. F., Chappell, A. E., Geary, R. S., Cheung, E., & Levin, A. A. (2002) · Analytical Biochemistry · doi:10.1006/abio.2002.5576 · Cited by 138
Sato, A., Takagi, M., Shimamoto, A., Kawakami, S., & Hashida, M. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.010 · Cited by 134
Repeated injections of PEG-PE liposomes generate anti-PEG antibodies.
Środa-Pomianek, K., Rydlewski, J., Langner, M., Kozubek, A., Grzybek, M., & Sikorski, A. F. (2005) · PubMed · Cited by 116
Mishra, S., Heidel, J. D., Webster, P. C., & Davis, M. E. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.06.018 · Cited by 115
Self-citationRobbins, M., Li, M., Leung, I., Li, H., Boyer, D. V., Song, Y., Behlke, M. A., & Rossi, J. J. (2006) · Nature Biotechnology · doi:10.1038/nbt1206 · Cited by 111
Ligand-Targeted Delivery of Therapeutic siRNA
Ikeda, Y., & Taira, K. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9001-x · Cited by 102
Kulkarni, R. P., Mishra, S., Fraser, S. E., & Davis, M. E. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050081u · Cited by 67
Self-citationGokhale, P. C., Zhang, C., Newsome, J. T., Pei, J., Ahmad, I. N., Rahman, A., Dritschilo, A., & Kasid, U. N. (2002) · PubMed · Cited by 60
Antineoplastic drugs that interfere with iron metabolism in cancer cells
Head, J. F., Wang, F., & Elliott, R. L. (1997) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(96)00010-6 · Cited by 53
Formstecher, É., Reverdy, C., Cholay, M., Planquette, C., Trouplin, V., Lehrmann, H., Aresta, S., Calabrese, A., Arar, K., Daviet, L., et al. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.387 · Cited by 16
Arnaud, C. H. (2006) · Chemical & Engineering News · doi:10.1021/cen-v084n046.p016 · Cited by 4
Cited by
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Self-citationFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Self-citation
Metadata
- Authors
- Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-04-03
- Volume
- 104
- Issue
- 14
- Pages
- 5715-5721
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2140093304
- Cited by
- 382
- References
- 39
- FWCI
- 15.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.